Breaking News

Agere Expands Manufacturing Capabilities

November 6, 2012

Adds cGMP spray drying services

Agere Pharmaceuticals has added cGMP manufacturing capabilities to support clients entering Phase IIb trials. The new capacity extends services for formulation development to oral bioavailability of BCS II and IV compounds.  
 
“We’ve extended our cGMP spray drying capabilities in response to our clients’ requests to continue with Agere as they enter Phase IIb clinical trials,” said Marshall Crew, Agere’s president and chief executive officer. “This is a natural progression for us, as expanding services delivers efficiencies to our clients.”
blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.